Redeye provides its initial take on Heliospectra’s Q3 results, which were largely in line with expectations. Sales came in slightly above forecast, while the cost base was as expected. Management remains optimistic, with an expanding business pipeline and increasing market visibility. We anticipate only minor adjustments to our estimates.
LÄS MER
